Atul Dandekar, serving as the Chief Scientific and Business Officer for Maze Therapeutics, Inc. (NASDAQ:MAZE), finalized a set of stock transactions on June 29, 2026. The executive's activities involved both the disposition and acquisition of company equity, executed under a structured trading framework.
Dandekar sold 7,500 shares of Maze Therapeutics common stock at a per-share price of $28.02. The total proceeds from this sale amounted to $210,150. In a concurrent transaction, the executive acquired an identical number of shares, 7,500, through the exercise of stock options. The exercise price for these options was set at $10.42 per share, resulting in a total transaction value of $78,150 for the acquired shares.
All reported transactions were carried out under a Rule 10b5-1 trading plan. Dandekar established this pre-arranged plan on September 29, 2025, providing a structured framework for the execution of these trades. The stock options that were exercised were fully vested as of March 17, 2025.
Following these transactions, Dandekar's direct holdings in Maze Therapeutics common stock total 26,250 shares. This position includes 1,442 shares acquired through the company's Employee Stock Purchase Plan. Additionally, the executive holds 29,143 derivative securities in the form of stock options.
The stock activity occurs against a backdrop of significant price movement for Maze Therapeutics. The stock price has risen to $29.81, marking an 11.89% gain over the past week and a 155.92% return over the last year. According to InvestingPro analysis, MAZE currently appears overvalued relative to its Fair Value. The Relative Strength Index (RSI) suggests overbought territory, indicating potential near-term volatility or correction risks.